PL2833907T3 - Kompozycje i sposoby hamowania masp-1 i/lub masp-3 do leczenia napadowej nocnej hemoglobinurii - Google Patents

Kompozycje i sposoby hamowania masp-1 i/lub masp-3 do leczenia napadowej nocnej hemoglobinurii

Info

Publication number
PL2833907T3
PL2833907T3 PL13798222T PL13798222T PL2833907T3 PL 2833907 T3 PL2833907 T3 PL 2833907T3 PL 13798222 T PL13798222 T PL 13798222T PL 13798222 T PL13798222 T PL 13798222T PL 2833907 T3 PL2833907 T3 PL 2833907T3
Authority
PL
Poland
Prior art keywords
masp
inhibting
compositions
treatment
methods
Prior art date
Application number
PL13798222T
Other languages
English (en)
Inventor
Hans-Wilhelm Schwaeble
Gregory A. Demopulos
Original Assignee
Omeros Corporation
University Of Leicester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omeros Corporation, University Of Leicester filed Critical Omeros Corporation
Publication of PL2833907T3 publication Critical patent/PL2833907T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
PL13798222T 2012-04-06 2013-04-05 Kompozycje i sposoby hamowania masp-1 i/lub masp-3 do leczenia napadowej nocnej hemoglobinurii PL2833907T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261621461P 2012-04-06 2012-04-06
PCT/US2013/035488 WO2013180834A2 (en) 2012-04-06 2013-04-05 Compositions and methods of inhibting masp-1 and/or masp-3 for the treatment of paroxysmal nocturnal hemoglobinuria
EP13798222.9A EP2833907B1 (en) 2012-04-06 2013-04-05 Compositions and methods of inhibting masp-1 and/or masp-3 for the treatment of paroxysmal nocturnal hemoglobinuria

Publications (1)

Publication Number Publication Date
PL2833907T3 true PL2833907T3 (pl) 2018-08-31

Family

ID=49325295

Family Applications (2)

Application Number Title Priority Date Filing Date
PL18158799T PL3366307T3 (pl) 2012-04-06 2013-04-05 Kompozycje i sposoby hamowania masp-1 i/lub masp-2 i/lub masp-3 do leczenia napadowej nocnej hemoglobinurii
PL13798222T PL2833907T3 (pl) 2012-04-06 2013-04-05 Kompozycje i sposoby hamowania masp-1 i/lub masp-3 do leczenia napadowej nocnej hemoglobinurii

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL18158799T PL3366307T3 (pl) 2012-04-06 2013-04-05 Kompozycje i sposoby hamowania masp-1 i/lub masp-2 i/lub masp-3 do leczenia napadowej nocnej hemoglobinurii

Country Status (29)

Country Link
US (3) US20130273053A1 (pl)
EP (2) EP2833907B1 (pl)
JP (3) JP6366571B2 (pl)
KR (2) KR102142508B1 (pl)
CN (2) CN104661676A (pl)
AU (3) AU2013267909B2 (pl)
BR (1) BR112014024793A2 (pl)
CA (2) CA3087933A1 (pl)
CL (1) CL2014002694A1 (pl)
CY (1) CY1120736T1 (pl)
DK (2) DK2833907T3 (pl)
ES (2) ES2670668T3 (pl)
HR (1) HRP20180671T1 (pl)
HU (1) HUE036930T2 (pl)
IL (2) IL234991B (pl)
IN (1) IN2014KN02324A (pl)
LT (1) LT2833907T (pl)
MX (2) MX357540B (pl)
NO (1) NO2881536T3 (pl)
NZ (2) NZ629675A (pl)
PL (2) PL3366307T3 (pl)
PT (1) PT2833907T (pl)
RS (1) RS57266B1 (pl)
RU (2) RU2018114903A (pl)
SI (1) SI2833907T1 (pl)
SM (1) SMT201800253T1 (pl)
TR (1) TR201806939T4 (pl)
WO (1) WO2013180834A2 (pl)
ZA (1) ZA201408100B (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE049154T2 (hu) * 2011-05-04 2020-09-28 Omeros Corp Készítmények a MASP-2-függõ komplement-aktiválás gátlására
BR112014031522A2 (pt) * 2012-06-18 2017-08-01 Omeros Corp métodos para inibir a ativação de complemento dependente de masp-3, para inibir a ativação de complemento dependente de masp-2 e para fabricar um medicamento
NZ629682A (en) 2013-03-15 2017-03-31 Omeros Corp Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
US20140363433A1 (en) 2013-03-15 2014-12-11 Omeros Corporation Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
JOP20170154B1 (ar) * 2016-08-01 2023-03-28 Omeros Corp تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة
JP7626577B2 (ja) 2016-11-28 2025-02-07 中外製薬株式会社 リガンド結合活性が調整可能なリガンド結合分子
BR112019008727A2 (pt) 2016-11-28 2019-07-16 Chugai Seiyaku Kabushiki Kaisha domínio de ligação ao antígeno, e polipeptídeo incluindo seção de transporte
WO2018186322A1 (en) * 2017-04-03 2018-10-11 Chugai Seiyaku Kabushiki Kaisha Anti-masp-1 antibodies and methods of use
TWI880235B (zh) 2017-11-28 2025-04-11 日商中外製藥股份有限公司 可調整配體結合活性的配體結合分子
JP7482630B2 (ja) 2017-11-28 2024-05-14 中外製薬株式会社 抗原結合ドメインおよび運搬部分を含むポリペプチド
IL311042B1 (en) 2018-05-29 2026-04-01 Omeros Corp MASP-2 inhibitors and methods of use
JP7414736B2 (ja) 2018-05-30 2024-01-16 中外製薬株式会社 アグリカン結合ドメインおよび運搬部分を含むポリペプチド
KR20220041846A (ko) * 2019-07-31 2022-04-01 바이오크리스트파마슈티컬즈,인코포레이티드 경구 보체 인자 d 억제제에 대한 투약 요법
IL293588B1 (en) 2019-12-04 2026-04-01 Omeros Corp 3-Amino-1-methylpyrazin-2(H1)-one derivatives as MASP-2 inhibitors, compositions containing them and uses thereof
EP4069676A1 (en) 2019-12-04 2022-10-12 Omeros Corporation Masp-2 inhibitors and methods of use
BR112022010895A2 (pt) 2019-12-04 2022-09-06 Omeros Corp Composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio associado à serina protease-2 associada à lectina de ligação ao manan
EP3916385A1 (en) * 2020-05-26 2021-12-01 Dynamic Biosensors GmbH Cell immobilization in fluid flow at high flow velocities
JP7634082B2 (ja) 2020-08-18 2025-02-20 オメロス コーポレーション 補体因子ｄを検出するためのモノクローナル抗体、組成物、および方法
CN114295594B (zh) * 2021-12-06 2023-09-19 贵州理工学院 一种基于分子信标筛选三螺旋DNA嵌入剂的“turn on”型荧光传感器
US20230265215A1 (en) * 2021-12-10 2023-08-24 Omeros Corporation Therapeutic antibodies that bind to the serine protease domain of masp-2 and uses thereof
CN121311247A (zh) * 2023-06-09 2026-01-09 舒泰神（北京）生物制药股份有限公司 特异性结合masp3的抗体以及特异性结合masp3和masp2的多特异性抗体

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5211657A (en) 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
EP0438803B1 (en) 1990-01-26 1997-03-12 Immunomedics, Inc. Vaccines against cancer and infectious diseases
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
ES2156149T3 (es) 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
US5856121A (en) 1994-02-24 1999-01-05 Case Western Reserve University Growth arrest homebox gene
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
CN1433466A (zh) * 1999-12-02 2003-07-30 詹斯·C·詹斯尼厄斯 Masp－3,一种固定补体的酶,及其应用
SG98393A1 (en) 2000-05-19 2003-09-19 Inst Materials Research & Eng Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
US7043719B2 (en) * 2001-07-23 2006-05-09 Intel Corporation Method and system for automatically prioritizing and analyzing performance data for one or more, system configurations
ES2601143T3 (es) 2002-07-19 2017-02-14 Omeros Corporation Copolímeros tribloque biodegradables, métodos de síntesis de los mismos, e hidrogeles y biomateriales preparados a partir de los mismos
US7666627B2 (en) * 2002-08-08 2010-02-23 Targetex Kft. Folded recombinant catalytic fragments of multidomain serine proteases, preparation and uses thereof
US20060140939A1 (en) * 2003-02-21 2006-06-29 Fung Sek C M Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury
US20050169921A1 (en) * 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
US20070253949A1 (en) * 2004-02-03 2007-11-01 Stefan Golz Diagnostics and Therapeutics for Diseases Associated with Plasma Kallikrein (KLKB1)
US7803931B2 (en) * 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
US8840893B2 (en) * 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
NZ612578A (en) 2005-08-19 2014-11-28 Abbvie Inc Dual variable domain immunoglobin and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
ATE419671T1 (de) * 2006-07-31 2009-01-15 Fiat Ricerche Durch eine fluidströmung betätigbarer elektrischer generator
JP5537420B2 (ja) 2007-05-31 2014-07-02 ユニヴァーシティ オブ ワシントン 標的遺伝子の誘導性変異誘発
CN102164960A (zh) * 2008-09-26 2011-08-24 罗氏格黎卡特股份公司 双特异性抗-egfr/抗-igf-1r抗体
US8637454B2 (en) * 2009-01-06 2014-01-28 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
WO2010102247A2 (en) * 2009-03-05 2010-09-10 Smith & Nephew, Inc. System, method, and apparatus for locating a femoral neck guide wire
US20120282285A1 (en) * 2009-07-17 2012-11-08 Rigshospitalet Masp isoforms as inhibitors of complement activation
CA2795311A1 (en) * 2009-11-05 2011-05-12 Taligen Therapeutics, Inc. Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
US8795973B2 (en) * 2010-11-29 2014-08-05 University of Leceister Methods for identifying inhibitors of mannan-binding lectin associated serine protease (MASP) proteins and uses thereof
BR112013025917A2 (pt) 2011-04-08 2016-12-20 Omeros Corp uso de um anticorpo masp-2 ou fragmento do mesmo que inibe ativação de complemento dependente de masp-2

Also Published As

Publication number Publication date
IL274721A (en) 2020-07-30
JP6815355B2 (ja) 2021-01-20
ZA201408100B (en) 2022-05-25
SI2833907T1 (en) 2018-07-31
MX2014012045A (es) 2015-05-15
TR201806939T4 (tr) 2018-06-21
RU2018114903A3 (pl) 2021-08-12
JP6366571B2 (ja) 2018-08-01
KR102318623B1 (ko) 2021-11-02
JP2015514117A (ja) 2015-05-18
BR112014024793A2 (pt) 2019-08-27
JP2021001199A (ja) 2021-01-07
MX357540B (es) 2018-07-13
CL2014002694A1 (es) 2015-08-28
SMT201800253T1 (it) 2018-07-17
KR102142508B1 (ko) 2020-08-10
WO2013180834A2 (en) 2013-12-05
AU2018200721B2 (en) 2020-03-26
NZ781091A (en) 2022-04-29
NZ727063A (en) 2021-10-29
AU2013267909B2 (en) 2018-03-01
NZ629675A (en) 2017-02-24
US20190382505A1 (en) 2019-12-19
JP2018162307A (ja) 2018-10-18
EP2833907A4 (en) 2016-03-16
AU2013267909A1 (en) 2014-11-27
HRP20180671T1 (hr) 2018-07-13
CN104661676A (zh) 2015-05-27
CY1120736T1 (el) 2019-12-11
RU2014144621A (ru) 2016-05-27
RU2018114903A (ru) 2019-03-04
EP2833907B1 (en) 2018-02-28
LT2833907T (lt) 2018-06-11
MX2018008658A (es) 2021-10-19
NO2881536T3 (pl) 2018-06-30
CA2869326C (en) 2021-09-21
MX388278B (es) 2025-03-18
AU2018200721A1 (en) 2018-02-22
DK3366307T3 (da) 2021-11-01
IL234991B (en) 2020-06-30
HUE036930T2 (hu) 2018-08-28
IN2014KN02324A (pl) 2015-05-01
ES2670668T3 (es) 2018-05-31
PL3366307T3 (pl) 2022-03-07
KR20200097808A (ko) 2020-08-19
WO2013180834A3 (en) 2014-04-03
CN121401408A (zh) 2026-01-27
RS57266B1 (sr) 2018-08-31
RU2655299C2 (ru) 2018-05-24
US20220242972A1 (en) 2022-08-04
IL274721B (en) 2022-04-01
DK2833907T3 (en) 2018-05-28
EP3366307A1 (en) 2018-08-29
IL234991A0 (en) 2014-12-31
US20130273053A1 (en) 2013-10-17
EP3366307B1 (en) 2021-07-28
ES2894944T3 (es) 2022-02-16
AU2020204163A1 (en) 2020-07-09
PT2833907T (pt) 2018-05-29
EP2833907A2 (en) 2015-02-11
KR20150003785A (ko) 2015-01-09
CA3087933A1 (en) 2013-12-05
CA2869326A1 (en) 2013-12-05
HK1206996A1 (en) 2016-01-22

Similar Documents

Publication Publication Date Title
LT2833907T (lt) Masp-1 ir (arba) masp-3 slopinančios kompozicijos ir būdai, skirti paroksizminės naktinės hemoglobinurijos gydymui
IL266582A (en) Preparations and methods for the treatment of hemoglobin diseases
EP2831001A4 (en) COMPOSITION FOR THE TREATMENT OF WATER AND METHOD FOR USE
SG11201601412XA (en) Compositions and methods for the treatment of presbyopia
EP2675469A4 (en) COMPOSITIONS, DEVICES AND METHODS OF USE THEREOF FOR THE TREATMENT OF CANCER
IL242483B (en) Preparations containing omomyc and their use for cancer treatment
ZA201408055B (en) Compositions and methods for the treatment of local pain
IL238177A0 (en) Methods and preparations for the treatment of cancer
EP2817018A4 (en) METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING OPHTHALMIC CONDITIONS
ZA201408056B (en) Compositions and methods for the treatment of mucositis
PL2830654T3 (pl) Sposoby i kompozycje do leczenia zapalenia
IL225793A0 (en) Methods and preparations for curing insulin-related medical conditions
IL236823A0 (en) Preparations for use in the treatment of bone defects
PL2968478T3 (pl) Kompozycje i sposoby do leczenia karboksyhemoglobinemii
PL2892556T3 (pl) Kompozycje i sposoby odnoszące się do leczenia chorób
IL238126B (en) Compositions for the treatment and prevention of obesity
ZA201503844B (en) Compositions and methods for treating dental caries
IL238602A0 (en) Preparations and methods for the treatment of ectodermal dysplasia
ZA201500111B (en) Compositions and methods for enhancing the efficacy of contraceptive microbicides
EP2934501A4 (en) USES AND METHOD FOR THE TREATMENT OF LIVER DISEASES OR DRESSES
ZA201408058B (en) Compositions and methods for the treatment of epilepsy
ZA201408065B (en) Compositions and methods for the treatment of diabetes
SG11201500838UA (en) Eprotirome for use in the prevention and/or treatment of hair disorders and compositions thereof
HK40131441A (en) Compositions and methods of inhibiting masp-1, masp-2 and/or masp-3 for the treatment of paroxysmal nocturnal hemoglobinuria
PL3079684T3 (pl) Kompozycje i sposoby do leczenia chorób związanych z układem renina-angiotensyna